• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Federal appeals court upholds Boston Scientific win in securities lawsuit

Federal appeals court upholds Boston Scientific win in securities lawsuit

August 8, 2011 By MassDevice staff

Boston Scientific

A federal appeals court disappointed a group of Boston Scientific Corp. (NYSE:BSX) shareholders hoping to recoup losses stemming from a recall of the Taxus Express drug-eluting stent, upholding a lower court decision to dismiss a securities fraud lawsuit.

The U.S. Court of Appeals for the First Circuit upheld last year’s ruling by Judge Douglas Woodlock of the U.S. District Court for Massachusetts to toss the class-action suit led by the Mississippi Public Employees’ Retirement System. In a single-page order, a three-judge circuit court panel dismissed the suit, awarded legal costs to Natick, Mass.-based Boston Scientific and sealed its opinion for seven days, unless the parties object to making the records public.

In April 2010, Woodlock ruled that the defendants failed to prove that Boston Scientific, ranked 10th on the MassDevice Big 100 list of the world’s largest medical device makers, concealed problems with the Taxus Express that led to a partial recall in 2004. The lawsuit involved cases of “no-deflate” in which the balloon catheter used to deploy the stents failed to deflate. The company discovered the problem as it geared up to launch the product in Europe in 2003 and prepared to apply for pre-market approval in the U.S. from the Food & Drug Administration and instituted a series of changes to its manufacturing process aimed at correcting the flaw, according to court documents. The defendants appealed Woodlock’s decision last spring.

The FDA approved the stent in March 2004; within first few weeks following the product launch, Boston Scientific received about 12 no-deflate reports and notice that one hospital was suspending its use of the device until “until it is determined if this is a product defect or an isolated incident,” according to court documents. BSX reported the no-deflate problems to the press in April of that year, saying that there was a very low rate of occurrence.

At the end of May a no-deflate incident caused the death of a patient, according to the documents, and the company received a second no-deflate report about one batch of the stents. The company recalled that batch in late June 2004 and another batch in July, representing a total of 200 stents. Boston Scientific said in a press release that the FDA received reports of one death and 16 serious injuries associated with no-deflates and eight reports that did not lead to injury. Of the 445,000 implantations as of July 2, 2004, the company said, there were 30 no-deflate complaints worldwide.

But on July 16 the company voluntarily recalled 96,000 stents, acknowledging in a press release three deaths and 43 serious injuries from deflation failures. Share prices plunged 10.3 percent on the news.

An FDA investigation of the manufacturing plants in Ireland and Minnesota that produced the stents found no violations, but Boston Scientific recalled another 3,000 stents that August. During the period covered by the suit — Nov. 20, 2003 to July 15, 2004 — former company executives including CEO James Tobin, co-founder and chairman Peter Nicholas, cardiovascular division president Paul LaViolette, chief technology officer Fredericus Colen and CFO Lawrence Best sold or gifted a total of $225.1 million in company stock.

Woodlock ruled that the evidence presented in the case showed that the company “had good reason to believe” that its manufacturing fixes had the problem under control in the fall of 2003 and “that the Taxus devices being manufactured at that time did not suffer from a no-deflate manufacturing defect,” according to court documents.

“Also of importance is the fact that the total number of complaints reported on Taxus stents by the end of the Class Period remained very small, roughly 45 complaints out of approximately 500,000 stents, an incidence rate of 0.009 percent. There is nothing in the record to suggest this incidence rate is out of proportion sufficiently to raise red flags given the type of procedure involved,” Woodlock wrote. “On this record, a reasonable jury could not find that the Defendants knew of or recklessly disregarded a ‘significant risk’ of no-deflate incidents. … Nor could a reasonable jury find that the Defendants were aware of a significant prospect for recalls until shortly before those recalls were undertaken.”

Woodlock also ruled that the insider trades the executives made were transacted during “open windows” following company earnings releases or under so-called “Rule 10b5-1” trading plans controlled by independent brokers. The executives also cleared the sales with Boston Scientific’s legal department before enacting the trades, the judge wrote, and either did not sell the share for personal benefit (Nicholas gifted $8.2 million worth of his stake), used the trades to boost their take in the company, made trades that conformed to normal sales patterns or “occurred during a period where the no-deflate issue was reasonably believed to have been resolved” or were not in a position to conceal news of the problems with the stents.

On the corporate level, Woodlock found no wrongdoing in Boston Scientific’s handling of the problems with the stent.

“[T]he evidence demonstrates a measured effort, in furtherance of a prudently cautious approach, by a corporation seeking to understand and correct the limitations of a product and to respond with appropriate adjustments. Even viewing the evidence in the light most favorable to Plaintiff, the corporate process evidenced in the record establishes a reasonable effort in light of developing information to address, rather than ignore, risks inherent in the launch of a product such as the Taxus stents,” he wrote, adding that the market was kept apprised of developments as the problems were investigated.

“[T]he record evidence establishes that the mere fact the Company stock price was inflated before the July 16 recall is insufficient in itself to prove that the alleged misrepresentations caused the economic loss alleged by Plaintiff,” Woodlock wrote.

Filed Under: Drug-Eluting Stents, Legal News, News Well Tagged With: Boston Scientific

In case you missed it

  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy